Retatrutide
IncretinInvestigationalreta · LY3437943
An investigational triple agonist. Not FDA-approved. Elevated disclaimer required on first add.
- Typical form
- Lyophilized vial
- Typical route
- Subcutaneous
- Display unit
- mg
- Typical vial
- 10 mg
- Half-life (approx.)
- 144 h
- Default in-use window
- 28 days
Educational · commonly logged
Typical protocol
A snapshot of how this compound is logged — not a prescription. You set every number.
- Common range
- 1–4 mg
- Starting log
- 2 mg
- Cadence
- Weekly
- Timing
- Once weekly in community research logs
- Duration
- Investigational — no labeled course
Not FDA-approved. Community logs cluster around 1–4 mg weekly. Purity and potency of non-approved products are not guaranteed.
Reconstitution note
Treat as a research vial. Concentration is whatever the user mixed — never assumed.
Storage
Fridge after mix. Research-use handling.
Cautions
Unapproved. Purity and potency of non-approved products are not guaranteed.
Evidence posture
Phase 3 / investigational. Not a marketed drug.